EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY-NC-ND 4.0

Final results of the CARO study: real-world adherence, effectiveness and patient-reported quality of life with carfilzomib-based regimens in German patients with relapsed/refractory multiple myeloma

Karin Potthoff, Jens Uhlig, Eyck von der Heyde, Christoph Losem, Arnd Nusch, Andreas Ammon, Björn Schöttker, Holger Schulz, Jan Janssen, Manfred Welslau, Stefan Wilop, Corinne Vannier und 6 weitere

Annals of Hematology · 08.10.2026 · 105 (11)

DOI: 10.1007/s00277-026-07302-8 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Annals of Hematology, online erschienen am 08.10.2026. Verfasst von Karin Potthoff und 17 weiteren Autor:innen. Beteiligte Einrichtung: Medical Department, iOMEDICO, Ellen-Gottlieb-Straße 19, 79106, Freiburg im Breisgau, Germany. manuscript@iomedico.com. Hauptthemen laut MEDLINE: Multiple Myeloma, Oligopeptides, Quality of Life, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Amgen Ltd..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The prospective, multicenter, non-interventional study CARO (NCT02970747) investigated adherence, effectiveness, quality of life and safety of carfilzomib in patients with relapsed/refractory multiple myeloma (RRMM) in German routine clinical practice. CARO included 359 patients at 69 sites and evaluated three carfilzomib-based treatment regimens: Carfilzomib with lenalidomide and dexamethasone (KRd), with dexamethasone only (Kd) or with daratumumab and dexamethasone (KdD). Across cohorts, patients’ adherence to carfilzomib was > 90%, while effectiveness was in line with previous data from both randomized clinical trials and real-world studies. Median PFS (95% CI) was 17.5 months (14.5, 24.7 [KRd]), 13.4 months (7.3, 18.1 [Kd]) and 20.1 months (10.9, 26.6 [KdD]), respectively. Median OS was 38.9 months (31.5, 51.4 [KRd]), 24.6 months (17.8, 36.8 [Kd]) and not reached (21.9, NA [KdD]). Patients’ quality of life remained stable during treatment, while pain parameters improved after 6 months of treatment. CARO provides real-world evidence that KRd, Kd, and KdD combinations achieve clinically meaningful outcomes in everyday practice and demonstrates patients’ excellent treatment adherence. ClinicalTrials.gov identifier: NCT02970747

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple MyelomaOligopeptidesQuality of LifeAntineoplastic Combined Chemotherapy ProtocolsPatient Reported Outcome MeasuresHumansFemaleDexamethasoneAgedMiddle AgedMaleProspective StudiesAntibodies, MonoclonalGermanyLenalidomideAged, 80 and overRecurrenceAdultTreatment Outcome

Stichwörter der Autor:innen

Antibody-based immunotherapyCarfilzomibChemotherapeutic approachesMyeloma

Substanzen

carfilzomibOligopeptidesDexamethasoneAntibodies, MonoclonalLenalidomidedaratumumab

Autor:innen und Institutionen

  • Medical Department, iOMEDICO, Ellen-Gottlieb-Straße 19, 79106, Freiburg im Breisgau, Germany. manuscript@iomedico.com.
  • Praxis Dr. Jens Uhlig, Naunhof, Germany.
  • Onkologische Schwerpunktpraxis, Hannover, Germany.
  • Rheinlandklinikum, Grevenbroich, Germany.
  • Praxis für Hämatologie und internistische Onkologie, Ratingen, Germany.
  • OSP Göttingen, Göttingen, Germany.

Förderung

  • Amgen Ltd.

Zitieren

APA

Potthoff, K., Uhlig, J., Heyde, E. V., Losem, C., Nusch, A., Ammon, A., Schöttker, B., Schulz, H., Janssen, J., Welslau, M., Wilop, S., Vannier, C., Hanselmann, J., Serrer, L., Woerner, S. M., Koszinowski, S., Engelhardt, M., & Knauf, W. (2026). Final results of the CARO study: real-world adherence, effectiveness and patient-reported quality of life with carfilzomib-based regimens in German patients with relapsed/refractory multiple myeloma. Annals of Hematology, 105(11). https://doi.org/10.1007/s00277-026-07302-8

Vancouver

Potthoff K, Uhlig J, Heyde EV, Losem C, Nusch A, Ammon A, et al. Final results of the CARO study: real-world adherence, effectiveness and patient-reported quality of life with carfilzomib-based regimens in German patients with relapsed/refractory multiple myeloma. Annals of Hematology. 2026;105(11). doi:10.1007/s00277-026-07302-8

BibTeX
@article{Potthoff2026,
  author = {Potthoff, Karin and Uhlig, Jens and Heyde, Eyck von der and Losem, Christoph and Nusch, Arnd and Ammon, Andreas and Schöttker, Björn and Schulz, Holger and Janssen, Jan and Welslau, Manfred and Wilop, Stefan and Vannier, Corinne and Hanselmann, Johanna and Serrer, Laura and Woerner, Sandra M and Koszinowski, Sophie and Engelhardt, Monika and Knauf, Wolfgang},
  title = {Final results of the CARO study: real-world adherence, effectiveness and patient-reported quality of life with carfilzomib-based regimens in German patients with relapsed/refractory multiple myeloma},
  journal = {Annals of Hematology},
  year = {2026},
  volume = {105},
  number = {11},
  doi = {10.1007/s00277-026-07302-8}
}
Kostenlos starten →